Abstract
Neutrophils may play an important role in the pathogenesis of severe asthma. Their infiltration into the airway is increased. Interleukin (IL)-8 is involved in this process, and is actually upregulated in the airways of patients. We have observed that in the absence of eosinophil chemoattractants, neutrophils stimulated by IL-8 augment eosinophil trans-basement membrane migration by releasing superoxide anion, matrix metalloproteinase, leukotriene B4 and platelet-activating factor. These findings suggest that IL-8-stimulated neutrophils could lead eosinophils to accumulate in the airways of asthmatic patients, which might be a mechanism for corticosteroid resistance in severe asthma. However, the mechanisms of IL-8 upregulation in the airway are not completely understood. Several studies suggest that IL-17 (or T helper 17 cells; Th17) is involved in the IL-8 upregulation observed in severe asthma. We clarified that dopamine induces Th17 differentiation through dopamine D1-like receptor (D1-like-R), and that the D1-like-R antagonist attenuates Th17-mediated diseases like experimental autoimmune encephalomyelitis. Furthermore, we demonstrated that a D1-like-R antagonist significantly suppressed ovalbumin (OVA)-induced neutrophilic airway inflammation in OVA T cell receptor-transgenic DO11.10 mice through inhibiting Th17-mediated immune responses. Therefore, dopamine D1-like-R antagonists could become useful for treating Th17-mediated neutrophil-dominant severe asthma. As inhaled corticosteroids are known to be less effective for controlling neutrophilic inflammation, a more effective therapeutic strategy for neutrophil-dominant asthma should still be elucidated.
Journal Section:
Review
References
1.
Bochner BS, Undem BJ, Lichtenstein LM: Immunological aspects of allergic asthma. Annu Rev Immunol 1994;12:295–335.
[PubMed]
2.
Gleich GJ: Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651–663.
[PubMed]
3.
Weller PF: Human eosinophils. J Allergy Clin Immunol 2000;100:283–287.
4.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144–2148.
[PubMed]
5.
Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA: Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655–1659.
[PubMed]
6.
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC, International Mepolizumab Study Group: A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062–1071.
[PubMed]
7.
Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001–1008.
[PubMed]
8.
The ENFUMOSA Study Group: The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470–477.
[PubMed]
9.
Kikuchi S, Kikuchi I, Hagiwara K, Kanazawa M, Nagata M: Association of tumor necrosis factor-α and neutrophilic inflammation in severe asthma. Allergol Int 2005;54:621–625.
10.
Kikuchi S, Nagata M, Kikuchi I, Hagiwara K, Kanazawa M: Association between neutrophilic and eosinophilic inflammation in patients with severe persistent asthma. Int Arch Allergy Immunol 2005;137(S1):7–11.
[PubMed]
11.
Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, Ludwig MS, Martin JG, Hamid Q: Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005;116:544–549.
[PubMed]
12.
Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, Cicora L, Ludwig M, Hamid Q, Martin JG: Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008;133:420–426.
[PubMed]
13.
Kikuchi S, Kikuchi I, Takaku Y, Kobayashi T, Hagiwara K, Kanazawa M, Nagata M: Neutrophilic inflammation and CXC chemokines in patients with refractory asthma. Int Arch Allergy Immunol 2009;149(S1):87–93.
[PubMed]
14.
Kikuchi I, Kikuchi S, Kobayashi T, Hagiwara K, Sakamoto Y, Kanazawa M, Nagata M: Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. Am J Respir Cell Mol Biol 2006;34:760–765.
[PubMed]
15.
Kobayashi T, Takaku Y, Kikuchi I, Soma T, Hagiwara K, Kanazawa M, Nagata M: Eosinophils do not enhance the trans-basement-membrane migration of neutrophils. Int Arch Allergy Immunol 2007;143(s1):38–43.
[PubMed]
16.
Kikuchi I, Kikuchi S, Kobayashi T, Takaku Y, Hagiwara K, Kanazawa M, Nagata M: Theophylline attenuates the neutrophil-dependent augmentation of eosinophil trans-basement membrane migration. Int Arch Allergy Immunol 2007;143:44–49.
[PubMed]
17.
Nagata M, Yamamoto H, Shibasaki M, Sakamoto Y, Matsuo H: Hydrogen peroxide augments eosinophil adhesion via β2 integrin. Immunology 2000;101:412–418.
[PubMed]
18.
Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 ten-fold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact. Blood 2000;96:2673–2681.
[PubMed]
19.
Goleva E, Hauk PJ, Hall CF, Liu AH, Riches DW, Martin RJ, Leung DY: Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J Allergy Clin Immunol 2008;122:550–559.
20.
Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, Hamid Q, Elias JA: Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004;304:1678–1682.
[PubMed]
21.
Hong JH, Hong JY, Park B, Lee SI, Seo JT, Kim KE, Sohn MH, Shin DM: Chitinase activates protease-activated receptor-2 in human airway epithelial cells. Am J Respir Cell Mol Biol 2008;39:530–535.
[PubMed]
22.
Pober JS, Gimbrone MA Jr, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA: Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986:137:1893–1896.
[PubMed]
23.
Smart SJ, Casale TB: TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. Am J Physiol 1994;266:238–245.
24.
Hiraguchi Y, Nagao M, Hosoki K, Tokuda R, Fujisawa T: Neutrophil Proteases Activate Eosinophil Function in vitro. Int Arch Allergy Immunol 2008;146(s1):16–21.
[PubMed]
25.
Liu H, Lazarus SC, Caughey GH, Fahy JV: Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. Am J Physiol 1999;276:L28–L34.
[PubMed]
26.
Randolph DA, Stephens R, Carruthers CJ, Chaplin DD: Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest 1999;104:1021–1029.
[PubMed]
27.
Randolph DA, Carruthers CJ, Szabo SJ, Murphy KM, Chaplin DD: Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999;162:2375–2383.
[PubMed]
28.
McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, Henry A, Irvin CG, Piganelli JD, Ray A, Kolls JK: TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008;81:4089–4097.
29.
Barczyk A, Pierzchala W, Sozanska E: Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003;97:726–733.
[PubMed]
30.
Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q: TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009;123:1185–1187.
[PubMed]
31.
Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392:245–252.
[PubMed]
32.
Murphy KM, Ouyang W, Farrar JD, Yang J, Ranganath S, Asnagli H, Afkarian M, Murphy TL: Signaling and transcription in T helper development. Annu Rev Immunol 2000;18:451–460.
[PubMed]
33.
Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA: Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000;106:551–559.
[PubMed]
34.
Matsushita S, Takagi R, Hashimoto K, Higashi T: Qualitative evaluation of adjuvant activities and its application to Th2/17 diseases. Int Arch Allergy Immunol 2011;155(s1):2–5.
[PubMed]
35.
Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S: Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2008;373:286–291.
[PubMed]
36.
Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S: Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol 2009;21:645–654.
37.
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol Rev 1998;78:189–225.
[PubMed]
38.
Hashimoto K, Inoue T, Higashi T, Takei S, Awata T, Katayama S, Takagi R, Okada H, Matsushita S: Dopamine D1-like receptor antagonist, SCH23390, exhibits a preventive effect on diabetes mellitus that occurs naturally in NOD mice. Biochem Biophys Res Commun 2009;383:460–463.
[PubMed]
39.
Okada H, Inoue T, Hashimoto K, Suzuki H, Matsushita S: D1-like receptor antagonist inhibits IL-17 expression and attenuates crescent formation in nephrotoxic serum nephritis. Am J Nephrol 2009;30:274–279.
[PubMed]
40.
Knott PG, Gater PR, Bertrand CP: Airway inflammation driven by antigen-specific resident lung CD4+ T cells in αβ-T cell receptor transgenic mice. Am J Respir Crit Care Med 2000;161:1340–1348.
41.
Wilder JA, Collie DD, Bice DE, Tesfaigzi Y, Lyons CR, Lipscomb MF: Ovalbumin aerosols induce airway hyperreactivity in naïve DO11.10 T cell receptor transgenic mice without pulmonary eosinophilia or OVA-specific antibody. J Leukoc Biol 2001;69:538–547.
42.
Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y: Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17:375–387.
[PubMed]
43.
Nakae S, Suto H, Berry GJ, Galli SJ: Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 2007;109:3640–3648.
44.
Nakagome K, Imamura M, Okada H, Kawahata K, Inoue T, Hashimoto K, Harada H, Higashi T, Takagi R, Nakano K, Hagiwara K, Kanazawa M, Dohi M, Nagata M, Matsushita S: Dopamine D1-like receptor antagonist attenuates Th17-mediated immune response and ovalbumin antigen-induced neutrophilic airway inflammation. J Immunol 2011;186:5975–5982.
45.
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910–1914.
[PubMed]
46.
Antonini A, Barone P: Dopamine agonist-based strategies in the treatment of Parkinson’s disease. Neurol Sci 2008;29(s5): S371–S374.
47.
Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST: Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012–1018.
[PubMed]
48.
Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P, T03 Asthma Investigators: A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549–558.
49.
Kraft M, Torvik JA, Trudeau JB, Wenzel SE, Martin RJ: Theophylline: potential anti-inflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996;97:1242–1246.
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
